drugset / Trial / NCT05245916
IBI397 or Combination Therapies in Patients With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or its Combination Therapies in Patients with Advanced Malignancies
Timeline
- Start
- 2022-04-14
- Primary completion
- 2023-08-24
- Completion
- 2023-08-24
Outcome
Outcome not reported
Stopped (Business): “Due to the company's development strategy adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI397 | Unknown | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |